scholarly journals Comorbidities of mental and behavioral disorders in chemically dependent patients in different periods of abstinence

2012 ◽  
Vol 61 (3) ◽  
pp. 139-147 ◽  
Author(s):  
Maria de Lourdes Pereira Costa ◽  
Luiz Carlos Marques de Oliveira
Keyword(s):  
Behavioral Disorders ◽  
Psychotic Disorders ◽  
Psychosocial Care ◽  
Response To Treatment ◽  
Additional Information ◽  
Icd 10 ◽  
Group 3 ◽  
Group 2 ◽  
Mental And Behavioral Disorders ◽  
Group 1

OBJECTIVE: To assess the frequency of comorbidities of mental and behavioral disorders (CMBD) in psychoactive substance (PAS)-dependent patients with different periods of abstinence cared for at Alcohol and Other Drug Psychosocial Care Centers (CAPS-ad). METHOD: All patients under treatment in the two CAPS-ad of the city of Uberlândia-MG, between April and September 2010, were consecutively assessed. The ICD-10 symptom checklist was used to diagnose CMBD; additional information was obtained from interviews and medical records. The patients were divided according to duration of abstinence: < 1 week (Group 1); 1-4 weeks (Group 2); and > 4 weeks (Group 3). RESULTS: Of all patients assessed, 62.8% were diagnosed with CMBD, which were more frequent (p < 0.05) in Group 1 (72%) than Group 3 (54.2%), and both groups were similar to Group 2 (61%). Depressive and anxiety disorders were more frequent among patients of Group 1. Mood disorders were more frequent (p < 0.05) in women [22/34 (65%) vs. 54/154 (35.1%)], whereas psychotic disorders were more frequent (p = 0.05) in men [16/154 (10.4%) vs. 0]. The presence of CMBD was associated with more severe clinical conditions. CONCLUSIONS: The higher frequency of diagnosis of CMBD in patients of Group 1 may have resulted from the difficulties in distinguishing mental disorders that are due to PAS intoxication or withdrawal from those that are not. However, to make the diagnosis of CMBD, even during detoxification, can increase the likelihood of better response to treatment.

The Effect of Information and Severity on Perception of Speakers With Adductor Spasmodic Dysphonia

2017 ◽  
Vol 26 (2) ◽  
pp. 327-341 ◽  
Author(s):  
Tanya L. Eadie ◽  
Reyhaneh Rajabzadeh ◽  
Derek D. Isetti ◽  
Martin T. Nevdahl ◽  
Carolyn R. Baylor
Keyword(s):  
Personal Characteristics ◽  
Spasmodic Dysphonia ◽  
Additional Information ◽  
Adductor Spasmodic Dysphonia ◽  
Diagnostic Labels ◽  
Vocal Effort ◽  
Personality Ratings ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

PurposeThe purpose of this study was to examine the effect of severity of adductor spasmodic dysphonia (ADSD) and information about it on unfamiliar listeners' attitudes about speakers' personal characteristics, perceived vocal effort, and listener comfort on the basis of ratings of speech recordings.MethodFifteen women with ADSD and 5 controls provided speech samples. Forty-five unfamiliar listeners were randomized into 3 groups. Listeners in Group 1 received no information, listeners in Group 2 were told that some speakers had voice disorders or had no voice concerns, and listeners in Group 3 were provided diagnostic labels for each speaker and information about ADSD. Listeners then rated speech samples for attitudes, perceived vocal effort, and listener comfort.ResultsSpeakers with ADSD were judged significantly worse than controls for attitudes related to “social desirability” and “intellect.” There was no effect of severity on “personality” attributes. However, provision of a diagnostic label resulted in significantly more favorable personality ratings than when no label was provided. Perceived vocal effort and comfort became significantly more negative as ADSD severity increased. Finally, most listener ratings were unaffected by provision of additional information about ADSD.ConclusionsListeners' perceptions about speakers with ADSD are difficult to change. Directions for counseling and public education need future study.

scholarly journals The Level of Reactive Carbonyl Derivatives of Proteins, Malondialdehyde, and Catalase Activity in the Brain of Rats after Therapy Following Chronic Unpredictable Moderate Stress

2020 ◽  
Vol 8 (A) ◽  
pp. 691-698
Author(s):  
Yelena Valerievna Yepifantseva ◽  
Mayra Galimzhanovna Abdrakhmanova ◽  
Yelena Vladimirovna Pozdnyakova ◽  
Polina Sergeyevna Semenikhina ◽  
Ruslan Andreevich Belyayev ◽  
...  
Keyword(s):  
Behavioral Disorders ◽  
Oxidative Metabolism ◽  
Protein Carbonylation ◽  
Carbonyl Derivatives ◽  
Group 4 ◽  
Group 3 ◽  
Group 2 ◽  
Derivatives Of ◽  
The Brain ◽  
Group 1

BACKGROUND: Understanding the mechanisms of the behavioral disorders’ emergence under the influence of chronic stress is the most important aspect of the subsequent development of a strategy for its therapy and prevention. Changes in the oxidative metabolism processes can be decisive in the development of the pathogenetic cascade in the brain. Information about these processes can be obtained by studying protein carbonylation, lipid peroxidation, and catalase activity (CA). The complexity of the therapeutic impact in various behavioral disorders implies the search for new pharmacological substances and the study of the previously known drugs’ effects based on the available scientific data. AIM: The aim of the study was to study the reactive carbonyl derivatives of proteins (RCDP), malondialdehyde (MDA), and CA in the brain of rats after therapy following chronic unpredictable moderate stress (CUMS). METHODS: Forty male outbred rats weighing 450–500 g were used in this study. For 21 days, all animals were exposed to the diverse stress factors for developing the CUMS. The animals were divided into four groups of 10 rats, each using randomized selection. The rats of one group were euthanized by decapitation with subsequent brain harvesting (Group 4). Remaining three groups of rats were treated with placebo (Group 1), harmine hydrochloride (Group 2), and amitriptyline (Group 3) for 21 days. Upon completion of therapy, all rats were also euthanized by decapitation with subsequent brain harvesting. The levels of RCDP, MDA, and CA were studied in their brain, and after that, we compared the multiple studied indicators in four groups. RESULTS: The results of the rat brain examinations in four groups showed that RCDP level in Group 2 was significantly lower than in Group 4 (p = 0.000). Similarly, in Group 1, it was lower than in Group 4 (p = 0.021), plus, it did not differ statistically from the harmine hydrochloride group (p = 1,000). Indicators of Groups 3 and 4 did not have any significant differences in RCDP level, too, (p = 0.799); however, the RCDP level in Group 2 was significantly lower than in Group 3 (p = 0.040). MDA indicators did not show significant differences; however, a tendency for lower values was revealed in Group 1 (p = 0.233) and Group 2 (p = 0.151). CA in Group 4 was lower than that in Group 1 (p = 0.000), Group 2 (p = 0.001), and Group 3 (p = 0.003) contemporaneously, while all treatment groups were comparable (p = 1.000). CONCLUSION: The result of exposure to chronic stress can be reproduced with the best quality in the CUMS model. The neurobiological foundations of the model make it possible to assess biochemical markers of oxidative metabolism and evaluate the possibilities of pharmacological correction of stress-induced behavioral disorders. To assess the mechanisms of autoregulation of oxidative metabolism, this study included a placebo group (Group 1), the level of RCDP in which was significantly higher in comparison with Group 3 and Group 4 and slightly lower than in Group 2. In this study, harmine hydrochloride demonstrated activity exceeding amitriptyline, particularly limiting the process of protein carbonylation, not noted for amitriptyline. According to the results of the RCDP assessment in the CUMS model, the process of protein carbonylation can be considered to be one of the significant factors in the deactivation of neurotransmitters. The CA levels determined in all groups allowed us to consider this marker as the most sensitive to the effects of stress, which possibly has an inhibitory effect on catalase, as its activity in all groups after therapy was more than two-fold higher than in animals right after CUMS. We can assume that CA plays an important role in starting the processes of autoregulation of oxidative metabolism. The study was carried out as a part of the implementation of the scientific and technical program No. BR05236584 “Development of new herbal preparations and their pharmacological and clinical studies” (O.0820). (2018–2020) in the priority area, “Life and Health Sciences.”

Molecular Imaging in the selection and evaluation of response in patients treated with Radium-223 in six different solid tumors: A single center experience

2020 ◽  
Author(s):  
SEVASTIAN MEDINA-ORNELAS ◽  
FRANCISCO OSVALDO GARCIA-PEREZ ◽  
MIGUEL Alvarez-Avitia ◽  
NORA SOBREVILLA-MORENO ◽  
ZAEL SANTANA-RIOS ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Solid Tumors ◽  
Tumor Burden ◽  
Response To Treatment ◽  
Radium 223 ◽  
Pet Ct ◽  
Significant Difference ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

Abstract Objective: Evaluate impact after 223 Ra therapy and 18 F-NaF (sodium fluoride) PET/CT in the selection and evaluation of response in patients treated with 223 Ra in six different solid tumors. Material and Methods: Twenty patients with metastatic castration-resistant prostate cancer (mCRPC), seven metastatic castration-sensitive prostate cancer (mCSPC), three osteosarcoma, two breast cancer, two non-small cell lung cancer (NSCLC), one chondrosarcoma, one chordoma and one patient lung neuroendocrine carcinoma. Three groups of study were defined according total skeletal tumor-burden obtained by 18 F-NaF PET/CT, group 1 <1000cm 3 , group 2 1001–2999cm 3 and group 3 >3000cm 3 VOI´s. A semi-quantitative comparison was performed measuring the SUVmax values of VOIs values in all bone metastases in each patient previous to receive the first cycle of 223 Ra, after 3 and 6 cycles. Results: 30 patients non-progress disease was documented after 24±4 weeks. 8 patients progress disease was presented after three cycles of 223 Ra, two patients with osteosarcoma, four patients with mCRPC, one patient with chondrosarcoma and one patient with NSCLC. Group 1 patients showed better response rates compared to group 3 (p<0.05). Group 2 patients who showed improvement clinical and radiological, had prostate malignancies compared to those in the same group, but non-prostatic malignancies (p<0.05). No significant difference in group 2 patients compared to group 3 (p<0.67). Symptomatic skeletal-related event was observed in 7 patients. Conclusion: 18 F-NaF PET/CT allows to identify patients who show osteoblastic bone activity and discard or confirm progression in the interval PET/CT image, allowing change of treatment, reducing costs. High tumor-burden strongly suggests a poor response to treatment

The Staircase Phenomenon

2001 ◽  
Vol 95 (2) ◽  
pp. 403-407 ◽  
Author(s):  
Aaron F. Kopman ◽  
Sanjeev Kumar ◽  
Monika M. Klewicka ◽  
George G. Neuman
Keyword(s):  
Mechanical Response ◽  
Additional Information ◽  
Laryngeal Mask Insertion ◽  
Train Of Four ◽  
Group 3 ◽  
Group 2 ◽  
American Society ◽  
Time Required ◽  
Few Data ◽  
Group 1

Background Repeated indirect stimulation enhances the evoked mechanical response of muscle (the staircase phenomenon). There are few data that document the magnitude of this effect in man. Inexpensive acceleromyographic monitors of neuromuscular function are now available. If these units are to be used as scientific tools or clinical monitors, additional information regarding how to achieve proper baseline stabilization and calibration is needed. Methods Anesthesia was induced and maintained with nitrous oxide, propofol, and an opioid. Tracheal intubation or laryngeal mask insertion was accomplished without muscle relaxants. Thirty adult patients classified as American Society of Anesthesiologists physical status I or II were divided into groups of 10. The mechanical response of the thumb to supramaximal ulnar nerve stimulation was recorded continuously with an acceleromyograph. Group 1 had train-of-four stimuli at 15-s intervals for 25 min. Group 2 had single stimuli at 1.0 Hz for 10 min. Group 3 had the same stimuli as group 1 except that a 50-Hz tetanus of 5 seconds' duration immediately preceded instrument calibration. Results In group 1, average twitch height (T1) increased rapidly to 148+/-19% (mean +/- SD) of control at 15 min and then more slowly to reach 158+/-26% of control at 25 min. The train-of-four fade ratio did not vary with the duration of stimulation. In group 2, T1 increased to 172+/-19% of control after 400 stimuli (6.7 min) and 180+/-22% of control at 10 min In group 3, average T1 did not decrease below 97+/-5% or increase above 105+/-15% of control at any time. Conclusions A 5-s, 50-Hz tetanus administered before initial twitch calibration considerably shortens the time required to achieve baseline stability.

scholarly journals Non-Group 1 Pulmonary Hypertension Associated With Systemic Sclerosis: An Under-studied Patient Population

2017 ◽  
Vol 16 (2) ◽  
pp. 68-75
Author(s):  
Zafia Anklesaria ◽  
Rajeev Saggar ◽  
Ariss Derhovanessian ◽  
Rajan Saggar
Keyword(s):  
Pulmonary Hypertension ◽  
Systemic Sclerosis ◽  
World Health ◽  
Response To Treatment ◽  
Specific Therapy ◽  
Pulmonary Manifestations ◽  
Group 3 ◽  
Group 2 ◽  
The Impact ◽  
Group 1

Background: Systemic sclerosis (SSc) is a heterogeneous disorder that results in multiorgan dysfunction. The most common pulmonary manifestations are pulmonary hypertension (PH) and interstitial lung disease (ILD). Systemic sclerosis may be complicated by World Health Organization (WHO) Group 1 PH (SSc-PAH), which is the most well-studied subtype. The PH associated with SSc may also be secondary to underlying left heart disease (SSc-PH-LHD) or ILD (SSc-PH-ILD), and these subgroups are classified as WHO Group 2 and Group 3 PH, respectively. These non-WHO Group 1 PH subsets are notoriously under-studied. Available data suggest that the impact of PH-specific therapy in SSc-PH-LHD and SSc-PH-ILD is limited and survival is poor despite attempted treatment. Implication for clinicians: Most research and clinical trials surrounding PH in SSc have thus far focused on WHO Group 1 SSc-PAH. There are limited data surrounding therapeutic options for WHO Group 2 (SSc-PH-LHD) and Group 3 PH (SSc-PH-ILD) phenotypes. This review aims to summarize and consolidate the data surrounding these 2 distinct clinical phenotypes and to emphasize the available prognostic and treatment considerations. Conclusions: Given the unique pathophysiology, prognostic implications, and poor response to treatment of WHO Group 2 and 3 SSc-PH phenotypes, there is an overwhelming need for more data to best understand optimal management strategies. The focus should be individual patient-level prognostication, how and when to initiate and manage PH-specific therapy, and appropriate triage with regard to the timing of lung (or heart-lung) transplantation.

scholarly journals Anakinra After Corticosteroid and/or Tocilizumab Treatment in Patients with Severe COVID-19 Pneumonia and Moderate Hyperinflammation. A Retrospective Cohort Study.

2020 ◽  
Author(s):  
Ismael Francisco Aomar-MIllán ◽  
Juan Salvatierra ◽  
Ursula Torres-Parejo ◽  
Naya Faro-Miguez ◽  
José Luis Callejas-Rubio ◽  
...  
Keyword(s):  
Cohort Study ◽  
Clinical Laboratory ◽  
Interleukin 1 ◽  
Infectious Complications ◽  
Clinical Severity ◽  
Response To Treatment ◽  
Imaging Characteristics ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

Abstract Introduction: Little evidence appears to exists for the use of anakinra, a recombinant interleukin-1 receptor antagonist, after non-response to treatment with corticosteroids alone or combined with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammatory state. Patients and Methods: A retrospective observational cohort study was carried out involving 143 patients with severe COVID-19 pneumonia and moderate hyperinflammation. They received standard therapy along with pulses of methylprednisolone (group 1) or methylprednisolone plus tocilizumab (group 2), with the possibility of receiving anakinra (group 3) according to protocol. The aim of this study was to assess the role of anakinra in the clinical course (death, admission to the intensive care ward) during the first 60 days after the first corticosteroid pulse. Clinical, laboratory, and imaging characteristics as well as infectious complications were also analyzed.Results: 74 patients (51.7%) in group 1, 59 (41.3%) patients in group 2, and 10 patients (7%) in group 3 were included. 8 patients (10.8%) in group 1 died, 6 (10.2%) in group 2, and 0 (0%) in group 3. After adjustment for age and clinical severity indices, treatment with anakinra was associated with a reduced risk of mortality (adjusted hazard ratio 0.518, 95% CI 0.265-0.910; p=0.0437). Patients in group 3 had a lower mean CD4 count after 3 days of treatment. No patients in this group presented infectious complications.Conclusions: In patients with moderate hyperinflammatory state associated with severe COVID-19 pneumonia, treatment with anakinra after non-response to corticosteroids or corticosteroids plus tocilizumab therapy may be an option for the management of these patients, and may improve their prognosis.

scholarly journals PECULIARITIES OF THE COURSE OF COPD IN PATIENTS WITH DIFFERENT A46G (RS1042713) ALLELES OF ADRB2 GENE

2021 ◽  
Vol 29 (4) ◽  
pp. 30-34
Author(s):  
K. D. Dmytriiev ◽  
Y. M. Mostovoy ◽  
N. S. Slepchenko ◽  
N. I. Sinchuk
Keyword(s):  
Gene Polymorphism ◽  
Hospital Admissions ◽  
Response To Treatment ◽  
Chronic Obstructive ◽  
Duration Of Treatment ◽  
Obstructive Pulmonary Disease ◽  
Group 3 ◽  
Adrb2 Gene ◽  
Group 2 ◽  
Group 1

PECULIARITIES OF THE COURSE OF COPD IN PATIENTS WITH DIFFERENT A46G (RS1042713) ALLELES OF ADRB2 GENE K. D. Dmytriiev, Y. M. Mostovoy, N. S. Slepchenko, N. I. Sinchuk Abstract A significant number of genetic factors, modulating inflammation, fibrosis and bronchial responsiveness, plays an important role in development of chronic obstructive pulmonary disease. Particularly, polymorphism of ADRB2 gene is associated with the development and severity of COPD, as well as with a response to beta-2 agonists. Aim — to study the prevalence of ADRB2 gene polymorphism among COPD patients and to reveal its possible relationship with the development of COPD and its clinical course. Materials and methods. 100 patients with the diagnosis of COPD were included into the study. An mean age was 64.09 ± 1.94 years. There were 66 men (66 %) and 34 women (34 %). There were 68 smokers (68 %), an average smoking experience was 24,44 ± 4,84 pack-years. Mean COPD duration was — 9.35 ± 2.42 years. We collected data about the amount of exacerbations, use of antibiotics, glucocorticoids, methylxanthines, data of mMRC and CAT questionnaires in all patients. Questionnaire data were collected during three visits — visit of inclusion, visit 2 (5±1 weeks), visit 3 (1 year). Data about exacerbation and drugs use were collected for the year prior to the study and the year of participation. Results. Regarding the presence of ADRB2 gene polymorphism all patients were allocated to 3 groups: group 1 — 23 (23 %) A46A allele carriers; group 2 - 39 (39 %) A46G allele cariers and group 3 — 38 (38 %) G46G allele carriers. Duration of COPD was greater in group 3 compared to the group 1 (7,08±1,59 vs 10,5±0,98) (p < 0,05). Group 2 and group 3 had greater proportion of patients with COPD GOLD D (46,15±8,32 % and 44,73±8,28 % correspondingly), when compared to group 1 (17,39±8,38 %) (p < 0,05). Group 1 had less exacerbations (2,13 ± 0,22) when compared to group 2 (2,97 ± 0,28), and group 3 (2,86 ± 0,25) (p < 0,05). Duration of treatment with antibiotics was significantly shorter in A46A allele carriers (8,61 ± 1,60 days), when compared to two other groups (in group 2 - 13,64 ± 1,25 days, in group 3 - 13,00 ± 1,28 days) (p < 0,05). Duration of treatment with GCS in group 1 (2,95 ± 0,85 days), A46A allele carriers, was shorter when compared to group 2 (5,28 ± 0,94 days), A46G allele carriers (p < 0,05). Conclusions. Occurrence of polymorphic (A46G) and mutant (G46G) alleles of ADRB2 gene was associated with more severe course of COPD, greater amount of exacerbations and hospital admissions, greater need in antibiotics and GCS, indicating an important role of this gene in regulation of the airways responsiveness and response to treatment. Key words: COPD, ADRB2 gene polymorphism.

scholarly journals Features of spatial localization of dental plaque during orthodontic treatment on braces

2020 ◽  
Vol 24 (3) ◽  
pp. 141-145
Author(s):  
Malkan A. Amkhadova ◽  
O. A. Zorina ◽  
O. A. Boriskina ◽  
N. B. Petrukhina ◽  
A. A. Nechaev
Keyword(s):  
Dental Plaque ◽  
Orthodontic Treatment ◽  
Spatial Localization ◽  
Additional Advantage ◽  
Group I ◽  
Icd 10 ◽  
Manual Toothbrush ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

The aim of the study was to evaluate the features of spatial localization of dental plaque in patients with braces, depending on the type of toothbrush used. We enrolled 63 patients from 11 to 18 years old, needing orthodontic treatment on a bracket system due to the tight position of the teeth in unilateral cleft palate and lip (Q37.1 according to ICD-10) after reconstructive surgery, in combination with mesial occlusion (K07.2 according to ICD-10). Material and methods: We evenly divided all participants into three groups depending on the type of brush used. Group 1 (n = 21) patients used an orthodontic manual toothbrush (Professor persin, Spazzolificio Piave S. p.A, Italy). Group 2 (n = 22) patients used an ultrasonic toothbrush (Emmi-dent, EMAG AG, Germany) and group 3 (n = 20) used an electric toothbrush (Oral-B Pro-Expert, Procter Gamble, USA). To assess the level of hygiene and determine the spatial accumulation of plaque, we used the Silness Loe index in the modification of Williams P. et al. (1991) at various stages. These included one week after professional hygiene after fixing both arcs. Then, six, and twelve months of wearing them. Material and methods: Group I contained the most pronounced deterioration in the hygienic state of the oral cavity during orthodontic treatment using a manual brush. Predominantly, the plaque accumulated in pricesavvy region. Uneven distribution of dental plaque relative to orthodontic techniques in group 1 was found in all quadrants of the upper and lower jaw.Conclusion: When assessing the spatial distribution of dental plaque relative to the bracket systems, it was possible to identify an additional advantage of using an ultrasonic brush. In comparison with an electric brush, we observed slight expressions in plaque accumulation on the four surfaces of the tooth., In the posterior area, plaque accumulated without pronounced deviations from the other areas of the tooth.

scholarly journals The interoperability between the Spanish version of the International Classification of Diseases and ORPHAcodes: towards better identification of rare diseases

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Juan Rico ◽  
Luis Javier Echevarría-González de Garibay ◽  
María García-López ◽  
Sandra Guardiola-Vilarroig ◽  
Luis Alberto Maceda-Roldán ◽  
...  
Keyword(s):  
Healthcare System ◽  
Rare Diseases ◽  
International Classification Of Diseases ◽  
International Classification ◽  
Classification Of Diseases ◽  
Icd 10 ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

Abstract Background Rare diseases present a wide spectrum of clinical manifestations and severity levels and are often poorly known and underrepresented, making them difficult to classify. Diagnoses are usually coded using the International Classification of Diseases (ICD), with its different versions. In Spain, the ICD-10-ES (stem from the ICD-10-CM–Clinical Modification) is used throughout the National Healthcare System since 2016, indistinctively including rare diseases that often lack a specific code. Orphanet aims to provide high-quality resources on rare diseases. The goal was to interrelate the Orphanet classification with the ICD-10-ES in order to engage a tool to track rare diseases diagnosis and characterize the improvement space for the identification of rare diseases patients in the Spanish Healthcare System. Methods 5775 disorder level ORPHAcodes were mapped to ICD-10-ES codes by comparing the descriptors associated in both classifications. ORPHAcodes were then clustered based on their assigned ICD-10-ES chapter and the redundancy of each individual ICD-10-ES code was calculated by counting the ORPHAcodes they mapped to. Three groups were established: Group 1 (1 ORPHAcode per ICD-10-ES), Group 2 (between 2–49 ORPHAcodes per ICD-10-ES) and Group 3 (≥ 50 ORPHAcodes per ICD-10-ES). Results Equivalences to 1700 ICD-10-ES codes were established for 5664 ORPHAcodes. The ORPHAcodes distribution within the ICD-10-ES showed an aggregation in the “Q” (> 40%), “G” (> 14%), and “E” (12%) chapters. The availability of ICD-10-ES codes to map ORPHAcodes reached its lowest at the “G” and “Q” chapters with less than 0.2 ICD-10-ES codes available per ORPHAcode. Global ICD-10-ES codes redundancy analysis revealed that only 1055 of the equivalences pertain to group 1. Group 2 contained 3358 equivalences with 634 ICD-10-ES codes while 1322 equivalences were group 3 (11 ICD-10-ES). Within ICD-10-ES chapters, “G” and “Q” contained over 30% and 45% of their own equivalences in the highest redundancy level (group 3) respectively, but under 10% one to one equivalences each (group 1). Conclusions ICD-10-ES codes have not enough specificity to identify rare diseases. Direct mapping between ICD and ORPHAcodes or the integration of ORPHAcodes at the healthcare system for diagnoses codification would enable better detection and epidemiological analysis of rare diseases.

scholarly journals Serum CA-125: biomarker of pulmonary tuberculosis activity and evaluation of response to treatment

2012 ◽  
Vol 35 (4) ◽  
pp. 223 ◽  
Author(s):  
Füsun Şahin ◽  
Pinar Yildiz
Keyword(s):  
Pulmonary Tuberculosis ◽  
Post Treatment ◽  
Response To Treatment ◽  
Ca 125 ◽  
Significant Difference ◽  
Group 3 ◽  
Group 2 ◽  
Tuberculosis Activity ◽  
Group 1

Purpose: CA-125 is a high molecular weight mucin-like glycoprotein and an ovarian cancer antigen. Elevated CA-125 levels are also seen with various other benign and malignant conditions. In this study, the ability of CA-125 to predict pulmonary tuberculosis activity was investigated. Methods: This analytical study included 42 cases with active tuberculosis (Group 1), 35 cases with  inactive tuberculosis  (Group 2) and 20 healthy subjects (Group 3). CA-125 measurements were taken in all three groups. Measurements in Group 1 were repeated after completing a two month anti-tuberculosis treatment in 38 of the 42 patients. Results: Mean serum CA-125 level for Group 1 was 76.48±24.71 U/mL, which was significantly higher than levels in Group 2 (20.01±7.89 U/mL) and Group 3 (18.32±2.87 U/mL) (p < 0.001). Of the 38 patients in Group 1 who were studied both pre- and post-treatment, CA-125 levels decreased significantly: from 78.88±24.72 U/mL before treatment to 22.78±8.02 U/mL after treatment (p < 0.001). There was no statistically significant difference between the  post-treatment  values  of   Group 1 and either Group 2 and Group 3 values (p > 0.05).  Group 2 and Group 3 levels were not  significantly different (p > 0.05). The cut-off level for accurate determination of activity was 36.35 U/mL. The sensitivity at this level was 97.6% and specificity was 100%. Conclusion: Our findings suggest that CA-125 can be a beneficial parameter in determination of pulmonary tuberculosis activity and the evaluation of response to treatment.

Sign in / Sign up

Export Citation Format

Share Document